No label defined (Q32871)
Jump to navigation
Jump to search
No description defined
- Tumors, Treatments, and Trust: Cancer Characteristics, Outcomes, and Screening Uptake in Transgender and Gender-Diverse Patients.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
More than 2.5 million adults in the United States identify as transgender or gender-diverse (TGD), but little data exist on cancer screening and care for this population. (English)
BACKGROUND (English)
© 2024. Society of Surgical Oncology. (English)
2024
We examined cancer characteristics, screening adherence, genetic testing, and provider inclusive language for TGD patients with cancer. (English)
BACKGROUND (English)
© 2024. Society of Surgical Oncology. (English)
2024
This single institution retrospective cohort study identified TGD patients with cancer between 2000 and 2022. (English)
METHODS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Demographic, clinicopathological, treatment, and screening data were collected, as well as data on gender-affirming care (GAC) and use of patients' personal pronouns in medical records. (English)
METHODS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Descriptive statistics and regression analyses were used to report outcomes. (English)
METHODS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Sixty unique patients with 69 cancer diagnoses were included: 63.3% were transgender women, 21.7% transgender men, 6.7% nonbinary, and 8.3% were genderqueer. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Sixty-five percent had a family history of cancer. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Only 46.2% of those who met genetic testing criteria were referred. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
On review of recommended cancer screening, colorectal screening had the greatest uptake (62%), followed by breast (48.3%), lung (35.7%), cervical (33.3%), and prostate (32%); 8.5% of cancers were diagnosed on screening. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Individuals with Medicare had reduced odds of screening uptake (OR 0.07, 95% CI 0.01-0.58) versus private insurance. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
With respect to GAC, 73.3% used gender-affirming hormone therapy and 41% had gender-affirming surgery. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
After initiating GAC and asserting personal pronouns, 75% were referred to by incorrect name/pronouns in provider documentation. (English)
RESULTS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Our TGD cancer patient cohort had low rates of disease-specific cancer screening and inadequate genetic referrals. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Many providers did not use appropriate patient names/pronouns. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Provider and patient interventions are needed to ensure inclusive preventative and oncologic care for this marginalized population. (English)
CONCLUSIONS (English)
© 2024. Society of Surgical Oncology. (English)
2024
Alexandra C (English)
Istl (English)
AC
Samuel (English)
Lawton (English)
S
Andrew E (English)
Petroll (English)
AE
Chandler S (English)
Cortina (English)
CS
15 August 2024
8 August 2024